American Society of Hematology (ASH)

The American Society of Hematology (ASH) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal, Blood Advances.

Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)

Researchers presented updated safety and efficacy results of a 2-part study (GEN503) that evaluated combination therapy with the anti-CD38 monoclonal antibody daratumumab plus lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (RRMM). Read More ›

Natural History of Relapsed MM After Initial Relapse

Researchers reported results of a global, multicenter, retrospective International Myeloma Working Group study that assessed the current treatment approaches utilized for initial treatment after first relapse and salvage treatment of patients with multiple myeloma (MM), and examined patient outcomes following successive therapies with the goal of examining the natural history of relapsed MM. Read More ›

Ixazomib plus Lenalidomide/Dexamethasone Significantly Prolongs Progression-Free Survival for Patients with RRMM in the Phase 3 Tourmaline-MM1 Study

Researchers presented results of the randomized, placebo-controlled phase 3 Tourmaline-MM1 study that evaluated the benefit of adding the oral proteasome inhibitor ixazomib to the lenalidomide and dexamethasone (Rd) backbone compared with placebo plus Rd in patients with relapsed and/or refractory multiple myeloma (RRMM). Read More ›

The Impact of New Multiple Myeloma Treatments

Beth Faiman expresses her excitement about the newly approved multiple myeloma treatments but believes that they will also bring about new challenges. Read More ›

Bortezomib/Thalidomide/Dexamethasone (VTD) Is Superior to Bortezomib/Cyclophosphamide/ Dexamethasone (VCD) Prior to ASCT for Patients with De Novo MM

Researchers presented results of the randomized, prospective IFM 2013-04 trial that compared the induction treatment regimens of bortezomib/thalidomide/dexamethasone and bortezomib/cyclophosphamide/dexamethasone prior to autologous stem-cell transplant (ASCT) in patients with de novo multiple myeloma (MM). Read More ›

In-Depth Molecular Profiling of Multiple Myeloma in African Americans

Researchers reported results of in-depth molecular profiling performed on samples from African Americans and European Americans with multiple myeloma enrolled in the longitudinal CoMMpass study. Read More ›

Factors Influencing Second-Line Treatment with Triplet Therapy for Patients with RRMM in Routine Care

This study assessed factors that influenced the use of 3-drug combination therapy as a second-line treatment choice in patients with relapsed/refractory multiple myeloma (RRMM) who were managed in routine care. Read More ›

MRD Negativity Is Critical for Prolonged Remissions in High- and Standard-Risk MM

In this study, the clinical value of minimal residual disease (MRD) status in achieving prolonged remissions was assessed in patients with multiple myeloma (MM) who had achieved at least very good partial response or complete response at 4 to 8 months and 12 to 24 months, or long-term relapse-free survivors (>6 years). Read More ›

Utilizing Patient Support Services

Beth Faiman argues that patient support services are integral in her role as a nurse because they aid in getting patients the treatments they need, promote adherence, and provide patient education. Read More ›

Durable Benefit with Addition of Elotuzumab to Lenalidomide/Dexamethasone in Patients with RRMM

Researchers presented updated results of the randomized phase 3 ELOQUENT-2 study that evaluated the anti-SLAM7 monoclonal antibody elotuzumab plus lenalidomide/dexamethasone versus lenalidomide/dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (RRMM). Read More ›

American Society of Hematology (ASH)

Page 4 of 44